Last reviewed · How we verify
Afstyla (LONOCTOCOG ALFA)
Afstyla (generic name: LONOCTOCOG ALFA) is a Recombinant protein drug developed by CSL Behring GmbH. It is currently FDA-approved (first approved 2017) for Hereditary factor VIII deficiency disease.
Afstyla is a recombinant factor VIII protein used to treat conditions such as Hemophilia A, Congenital Bleeding Disorder, and Kidney Disease. It works by replacing the missing or defective coagulation factor VIII in the body to help prevent bleeding.
At a glance
| Generic name | LONOCTOCOG ALFA |
|---|---|
| Sponsor | CSL Behring GmbH |
| Modality | Recombinant protein |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 2017 |
Approved indications
- Hereditary factor VIII deficiency disease
Common side effects
- Factor VIII inhibition (in previously untreated patients)
- Dizziness
- Hypersensitivity
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Afstyla CI brief — competitive landscape report
- Afstyla updates RSS · CI watch RSS
- CSL Behring GmbH portfolio CI
Frequently asked questions about Afstyla
What is Afstyla?
What is Afstyla used for?
Who makes Afstyla?
What is the generic name of Afstyla?
When was Afstyla approved?
What development phase is Afstyla in?
What are the side effects of Afstyla?
Related
- Manufacturer: CSL Behring GmbH — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Hereditary factor VIII deficiency disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing